Tarlatamab, a First-In-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small Cell Lung Cancer: An Open-Label, Phase I Study.
Luis G Paz-AresStephane ChampiatW Victoria LaiHiroki IzumiRamaswamy GovindanMichael J BoyerHorst-Dieter HummelHossein BorghaeiMelissa Lynne JohnsonNeeltje SteeghsFiona BlackhallAfshin DowlatiNoemí ReguartTatsuya YoshidaKai HeShirish M GadgeelEnriqueta Felip FontYiran ZhangAmrita PatiMukul MinochaSujoy MukherjeeAmanda GoldrickDirk NagorsenNooshin Hashemi SadraeiTaofeek Kunle OwonikokoPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
In patients with heavily pretreated SCLC, tarlatamab demonstrated manageable safety with encouraging response durability. Further evaluation of this promising molecule is ongoing.
Keyphrases